The Latest Breaking News from Twist Bioscience

Twist Bioscience shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.

Twist Bioscience sees its Relative Strength Rating hit the 80-plus level.

A Relative Strength Rating upgrade for Twist Bioscience shows improving technical performance. Will it continue?

The DNA Data Storage Alliance introduced its inaugural specifications for DNA-based data storage this week. This specification outlines a method for encoding essential information within a DNA data archive, crucial for developing and commercializing an interoperable storage ecosystem. DNA data storage uses short strings of deoxyribonucleic acid (DNA) called oligonucleotides…

Cathie Wood's ARK Innovation is on top for the year again — racing back past Fidelity Blue Chip Growth. She can thank this stock.

Twist Bioscience beat quarterly expectations Friday and guided to "solid" sales growth for the upcoming year, leading TWST stock to rocket.

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies. The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates.  Ligands in this pathway are…

Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Twist Bioscience will report an earnings per share (EPS) of $-1.28.